The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy.
E. M. Posadas
No relevant relationships to disclose
N. M. Tannir
Research Funding - Abbott Laboratories
Y. Wong
No relevant relationships to disclose
M. S. Ernstoff
Stock Ownership - Abbott Laboratories (I)
C. K. Kollmannsberger
No relevant relationships to disclose
J. Qian
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
P. J. Ansell
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
E. M. McKeegan
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
M. D. McKee
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
J. L. Ricker
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
D. M. Carlson
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
M. D. Michaelson
Consultant or Advisory Role - Abbott Laboratories (U); AVEO (U); Genentech (U); Novartis (U); Pfizer (U); Wyeth (U)
Research Funding - Abbott Laboratories; Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer; Wyeth